


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. – 9. (Canceled).

10. (Currently Amended) A compound of formula (I)



(I)

or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof  
wherein:

X<sup>1</sup> is C=O;

X<sup>2</sup> is CR<sup>3</sup>;

X<sup>3</sup> is -NH-;

X<sup>4</sup> is CR<sup>4</sup>;

X<sup>5</sup> is CR<sup>5</sup>;

X<sup>6</sup> is CR<sup>6</sup>;

R<sup>1</sup> is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, or heteroaryl, provided that when R<sup>1</sup> is alkyl, substituted alkyl or alkenyl, R<sup>2</sup> is not cyano;

R<sup>2</sup> is cyano or a substituted or unsubstituted monocyclic heteroaryl group, provided that when R<sup>2</sup> is cyano R<sup>1</sup> is not alkyl, substituted alkyl or alkenyl;

R<sup>3</sup> is hydrogen, hydroxy, halogen, cyano, CO<sub>2</sub>R<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl or heteroaryl;

R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are independently selected from the group consisting of hydrogen, halogen, nitro, cyano,


O-R<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, SR<sup>7</sup>, S(O)R<sup>7</sup>, SO<sub>2</sub>R<sup>7</sup>, SO<sub>3</sub>R<sup>7</sup>, SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, CO<sub>2</sub>R<sup>7</sup>, C(O)NR<sup>8</sup>R<sup>9</sup>, C(O)alkyl, C(O)substituted alkyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;

R<sup>7</sup>, R<sup>10</sup>, and R<sup>11</sup>, are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O) substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocycloalkyl, C(O)heteroaryl, aryl, substituted aryl, heterocycloalkyl and heteroaryl; and


R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, alkynyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O)substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocycloalkyl, C(O)heteroaryl, aryl, substituted aryl, heterocycloalkyl, and heteroaryl or R<sup>8</sup> and R<sup>9</sup> taken together with the nitrogen atom to which they are attached complete a heterocycloalkyl or heteroaryl ring[;]

with the following proviso[s]:

(a) — when R<sup>1</sup> is substituted or meta unsubstituted phenyl, R<sup>3</sup> is H, R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H, then R<sup>2</sup> is not PhCONH<sub>2</sub>,



(b) — when R<sup>1</sup> is phenyl substituted with H, F, Cl, Br, I, CH<sub>3</sub>, CF<sub>3</sub>, OH, OCH<sub>3</sub>, OCF<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, NH<sub>2</sub>, NHCH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, O benzyl, C(=O)R<sub>9</sub>, or C(=O)OR<sub>9</sub> and R<sub>9</sub> is a lower alkyl group, R<sup>3</sup> is H, R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H, then R<sup>2</sup> is not




where Y is CH<sub>2</sub>, O or S, m and n are each greater than 1, and the sum of m and n is between 3 and 6; and

(c) when R<sup>2</sup> is heteroaryl, at least one of the heteroatoms must be O.

11. (Canceled)

12. (Currently Amended) A compound of Claim 10 of formula (III)



(III)

or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

R<sup>2</sup> is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, or substituted 5-oxazolyl;

R<sup>3</sup> is hydrogen, hydroxy, NR<sup>8</sup>R<sup>9</sup>, alkyl of 1 to 4 carbons, alkenyl of 2 to 4 carbons, alkynyl of 2 to 4 carbons, substituted alkyl of 1 to 4 carbons, phenyl, substituted phenyl, cycloalkyl of 5 to 7 carbons, substituted cycloalkyl of 5 to 7 carbons, monocyclic heterocycloalkyl and monocyclic heteroaryl;

R<sup>4</sup> is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, CF<sub>3</sub>, OCF<sub>3</sub>, OCH<sub>3</sub>, SCH<sub>3</sub>, S(O)CH<sub>3</sub>, or S(O)<sub>2</sub>CH<sub>3</sub>;

R<sup>5</sup> is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, vinyl, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CH=CF<sub>2</sub>, OCH<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, SCH<sub>3</sub>, S(O)CH<sub>3</sub>, or S(O)<sub>2</sub>CH<sub>3</sub>; and

R<sup>6</sup> is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, CF<sub>3</sub>, OCH<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>, S(O)CH<sub>3</sub>, and S(O)<sub>2</sub>CH<sub>3</sub>.

13. (Currently Amended) A compound of Claim 12 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

R<sup>2</sup> is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, or substituted 5-oxazolyl ~~or heteroaryl~~;

R<sup>3</sup> is hydrogen, hydroxy, halogen, methyl or NR<sup>8</sup>R<sup>9</sup>;

R<sup>4</sup> is hydrogen;

R<sup>5</sup> is halogen, methyl, ethyl, substituted alkenyl, alkyne, OMe or OCF<sub>3</sub>; and

R<sup>6</sup> is hydrogen.

14. (Currently Amended) A compound of Claim 13 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

R<sup>2</sup> is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl or substituted 5-oxazolyl;


R<sup>3</sup> is hydrogen, hydroxy, halogen or methyl;

R<sup>4</sup> is hydrogen;

R<sup>5</sup> is halogen, methyl or OMe; and

R<sup>6</sup> is hydrogen.

15. (Currently Amended) A compound of Claim 10 of formula (V)




(V)

or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof selected from:

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is




and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is CH<sub>3</sub> and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is CH<sub>3</sub>;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is Br;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is



and  $\text{R}^3$  is hydrogen;

a compound of formula (V) wherein:


$\text{R}^1$  is



and  $\text{R}^3$  is hydrogen;

a compound of formula (V) wherein:


$\text{R}^1$  is



and  $\text{R}^3$  is hydrogen;

a compound of formula (V) wherein:


$\text{R}^1$  is



and  $\text{R}^3$  is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:

R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;

a compound of formula (V) wherein:


R<sup>1</sup> is



and R<sup>3</sup> is hydrogen;





and a compound of formula (V) wherein:






R<sup>1</sup> is












and R<sup>3</sup> is hydrogen.





16. (Previously Amended) A compound of Claim 10 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof selected from:





































































































and



17. (Original) A pharmaceutical composition comprising a compound of Claim 10 and a pharmaceutically acceptable carrier.
18. (Original) A pharmaceutical composition comprising a compound of Claim 11 and a pharmaceutically acceptable carrier.
19. (Original) A pharmaceutical composition comprising a compound of Claim 12 and a pharmaceutically acceptable carrier.
20. (Original) A pharmaceutical composition comprising a compound of Claim 13 and a pharmaceutically acceptable carrier.
21. (Original) A pharmaceutical composition comprising a compound of Claim 14 and a pharmaceutically acceptable carrier.
22. (Original) A pharmaceutical composition comprising a compound of Claim 15 and a pharmaceutically acceptable carrier.
23. (Original) A pharmaceutical composition comprising a compound of Claim 16 and a pharmaceutically acceptable carrier.

24. --29. (Canceled)

30. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 10.

31. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 11

32. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 12.

33. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 13.

34. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising; administering a therapeutically effective amount of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

35. (Previously Added) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

36. (canceled).

37. (Previously Added) A method of claim 34 wherein: the phosphodiesterase Type 4 inhibitor is [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone].

38. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering an therapeutically effective amount of the pharmaceutical composition of Claim 17.

39. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and another agent known to be useful in treatment of such disorders.
40. (Previously Added) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and a phosphodiesterase Type 4 inhibitor.
41. (Previously Added) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and a phosphodiesterase Type 4 inhibitor.